Wall Street Zen downgraded shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) from a hold rating to a sell rating in a research note released on Saturday.
Separately, HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of TuHURA Biosciences in a research note on Friday, May 16th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.67.
Read Our Latest Analysis on HURA
TuHURA Biosciences Price Performance
Shares of HURA traded down $0.16 on Friday, hitting $2.46. 105,191 shares of the stock traded hands, compared to its average volume of 234,552. TuHURA Biosciences has a one year low of $1.80 and a one year high of $7.93. The business has a 50 day simple moving average of $3.59 and a 200 day simple moving average of $3.89.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02).
Institutional Trading of TuHURA Biosciences
A number of large investors have recently made changes to their positions in the business. Accent Capital Management LLC bought a new stake in shares of TuHURA Biosciences in the 4th quarter worth about $29,000. TT Capital Management LLC bought a new stake in shares of TuHURA Biosciences in the 4th quarter worth about $41,000. Jefferies Financial Group Inc. bought a new stake in shares of TuHURA Biosciences in the 4th quarter worth about $54,000. Bank of America Corp DE bought a new stake in shares of TuHURA Biosciences in the 4th quarter worth about $59,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of TuHURA Biosciences in the 4th quarter worth about $61,000. 0.62% of the stock is currently owned by institutional investors.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Recommended Stories
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
